Novartis says planned spinoff of Sandoz unit will take place around Oct. 4


By Adria Calatayud

Novartis said the planned spinoff of its Sandoz generic pharmaceuticals and biosimilars business is expected to occur on or around Oct. 4.

The Swiss pharmaceutical giant said Friday that the separation will take place through a proposed distribution of Sandoz shares to its existing shareholders. Novartis shareholders will get one Sandoz shares for every five Novartis shares held and one Sandoz American depositary receipts–or ADRs–for every five Novartis ADRs, the company said.

Novartis had previously said it expected the spinoff to happen early in the fourth quarter.

The Sandoz spinoff remains subject to approval by Novartis’s shareholders. Novartis has scheduled an extraordinary general meeting for Sept. 15 to vote on the proposed distribution of Sandoz shares and a reduction in its own share capital in connection with the spinoff, it said.

Following the separation, Sandoz would be listed in SIX Swiss Exchange, with an ADR program in the U.S., Novartis said.

Write to Adria Calatayud at

This article was originally published by Read the original article here.

Previous article: Adyen sees flurry of ratings moves after 39% price drop on Thursday
Next articleMarket Snapshot: U.S. stock futures pressured over rising yields, China trouble


Please enter your comment!
Please enter your name here